Abstract:Substance use disorders (SUDs) induce widespread molecular dysregulation in the nucleus accumbens (NAc), a brain region pivotal for coordinating motivation and reward. These molecular changes are thought to support lasting neural and behavioral disturbances that promote drug-seeking in addiction. However, different drug classes exert unique influences on neural circuits, cell types, physiology, and gene expression despite the overlapping symptomatology of SUDs. To better understand common and divergent molecular mechanisms governing SUD pathology, our goal was to survey cell-type-specific restructuring of the NAc transcriptional landscape in after psychostimulant or opioid exposure. We combined fluorescence-activated nuclei sorting and RNA sequencing to profile NAc D1 and D2 medium spiny neurons (MSNs) across cocaine and morphine exposure paradigms, including initial exposure, prolonged withdrawal after repeated exposure, and re-exposure post-withdrawal. Our analyses reveal that D1 MSNs display many convergent transcriptional responses across drug classes during exposure, whereas D2 MSNs manifest mostly divergent responses between cocaine and morphine, with morphine causing more adaptations in this cell type. Utilizing multiscale embedded gene co-expression network analysis (MEGENA), we discerned transcriptional regulatory networks subserving biological functions shared between cocaine and morphine. We observed largely integrative engagement of overlapping gene networks across drug classes in D1 MSNs, but opposite regulation of key D2 networks, highlighting potential therapeutic gene network targets within MSNs. These studies establish a landmark, cell-type-specific atlas of transcriptional regulation induced by cocaine and by morphine that can serve as a foundation for future studies towards mechanistic understanding of SUDs. Our findings, and future work leveraging this dataset, will pave the way for the development of targeted therapeutic interventions, addressing the urgent need for more effective treatments for cocaine use disorder and enhancing the existing strategies for opioid use disorder.

Viral vector-mediated gene therapy for opioid use disorders

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Shared and Divergent Transcriptomic Regulation in Nucleus Accumbens D1 and D2 Medium Spiny Neurons by Cocaine and Morphine

Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) As a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment

Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Angiogenic gene networks are dysregulated in opioid use disorder: evidence from multi-omics and imaging of postmortem human brain

Opioid use disorder: current trends and potential treatments

AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges

Viral vectors for therapy of neurologic diseases

AAV-based in vivo gene therapy for neurological disorders

Enhancing Protective Antibodies against Opioids through Antigen Display on Virus-like Particles

Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine

AI Derived Therapeutic Development for the Treatment of Opioid Use Disorder

Viral vector platforms within the gene therapy landscape

Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date

Adeno-associated virus vector as a platform for gene therapy delivery

Transcutaneous cervical vagus nerve stimulation reduces behavioral and physiological manifestations of withdrawal in patients with opioid use disorder: A double-blind, randomized, sham-controlled pilot study

Chemical Modification Strategies of Viral Vectors for Gene Therapy

Viral vector‐based gene therapies in the clinic

An emerging multi-omic understanding of the genetics of opioid addiction